Contraceptives, Oral, Combined
-
Subject Areas on Research
- 20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception.
- 20 µg versus >20 µg estrogen combined oral contraceptives for contraception.
- 20 µg versus >20 µg estrogen combined oral contraceptives for contraception.
- A randomized, double-blind study of two combined and two progestogen-only oral contraceptives.
- Antimullerian hormone and obesity: insights in oral contraceptive users.
- Continuous compared with cyclic use of oral contraceptive pills in the Dominican Republic: a randomized controlled trial.
- Continuous versus cyclic oral contraceptives for the treatment of endometriosis: a systematic review.
- Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agent.
- Depo medroxyprogesterone acetate (DMPA) and combined oral contraceptives and cervical carcinoma in-situ in women aged 50 years and under.
- Drug interactions between rifamycin antibiotics and hormonal contraception: a systematic review.
- Dual contraceptive method use for pregnancy and disease prevention among HIV-infected and HIV-uninfected women: the importance of an event-level focus for promoting safer sexual behaviors.
- Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide.
- Effects of an oral contraceptive combination with or without androgen on mammary tissues: a study in rats.
- Effects of estrogen/progestin agents on plasma retinoids and chylomicron remnant metabolism.
- Find alternatives for patients using 80 to 100 mcg estrogen OCs.
- Hormonal consequences of "missing the pill".
- Influence of oral contraceptives on the incidence of premalignant and malignant lesions of the cervix.
- Metabolic effects and efficacy of a triphasic oral contraceptive (norgestimate/ethinyl estradiol).
- Nonsurgical management of heavy menstrual bleeding: a systematic review.
- Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk.
- Risk-benefit assessment of the combined oral contraceptive pill in women with a family history of female cancer.
- Simultaneous quantitation of multiple contraceptive hormones in human serum by LC-MS/MS.
- Two-stage sampling in pharmaceutical applications.
- Women's ability to self-screen for contraindications to combined oral contraceptive pills in Tanzanian drug shops.
-
Keywords of People
- Berchuck, Andrew, James M. Ingram Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology